UK's Verona £44.7m Capital Raising To Be Followed By NASDAQ Listing

Verona Pharma PLC‘s capital raising will allow the Cardiff, UK-based biotech to progress its lead respiratory compound RPL554 through to a Phase III ready stage and sets the scene for a NASDAQ listing in the first quarter of 2017.